Nuvation Bio Inc. (NUVB) SEC filings

NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30105% above fair value

$3.99−0.07 (-1.72%)

Close on Nov 13, 2026Market cap $1.40BP/E –Yield –

SEC filings

40 of Nuvation Bio's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jun 30, 2026	Jul 6, 2026	SEC EDGAR
Current report	8-K	Jun 24, 2026	Jun 30, 2026	SEC EDGAR
Current report	8-K	May 21, 2026	May 27, 2026	SEC EDGAR
Current report	8-K	May 4, 2026	May 4, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 4, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 21, 2026	Apr 10, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 2, 2026	SEC EDGAR
Current report	8-K	Mar 2, 2026	Mar 2, 2026	SEC EDGAR
Current report	8-K	Jan 11, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Nov 26, 2025	Nov 26, 2025	SEC EDGAR
Current report	8-K	Nov 17, 2025	Nov 17, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 3, 2025	SEC EDGAR
Current report	8-K	Nov 3, 2025	Nov 3, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jun 11, 2025	Jun 11, 2025	SEC EDGAR
Current report	8-K	May 21, 2025	May 23, 2025	SEC EDGAR
Current report	8-K	May 7, 2025	May 7, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 7, 2025	SEC EDGAR
Proxy statement	DEF 14A	May 21, 2025	Apr 8, 2025	SEC EDGAR
Current report	8-K	Mar 21, 2025	Mar 25, 2025	SEC EDGAR
Current report	8-K	Mar 6, 2025	Mar 6, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 6, 2025	SEC EDGAR
Current report	8-K	Mar 3, 2025	Mar 5, 2025	SEC EDGAR
Current report	8-K	Mar 3, 2025	Mar 4, 2025	SEC EDGAR
Current report	8-K	Feb 11, 2025	Feb 12, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2024	Nov 6, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 6, 2024	SEC EDGAR
Current report	8-K	Oct 7, 2024	Oct 7, 2024	SEC EDGAR
Current report	8-K	Sep 3, 2024	Sep 5, 2024	SEC EDGAR
Current report	8-K	Aug 5, 2024	Aug 5, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 5, 2024	SEC EDGAR
Proxy statement	DEF 14A	Sep 3, 2024	Jul 30, 2024	SEC EDGAR
Current report	8-K	May 14, 2024	May 14, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 14, 2024	SEC EDGAR
Annual report, amended	10-K/A	Dec 31, 2023	Apr 26, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Nuvation Bio's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NUVB.

Compare: NUVB vs PBYI · NUVB vs HCM · NUVB vs RCUS · NUVB vs HRTX · NUVB vs IDYA

Revenue growth654.2% · median -4.4%

Operating margin-61.2% · median -71.4%

Net margin-67.4% · median -51.7%

Company	Revenue	Growth
IDYA	$234.13M	–
PBYI	$231.83M	+9.4%
HCM	$204.89M	-4.3%
NUVB	$201.73M	+654.2%
HRTX	$148.22M	-4.4%
RCUS	$100.00M	-58.3%

Company

Next earnings (est.): Mar 1, 2027, during market hours
Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 298
Held by institutions: 66.5%
Auditor: KPMG LLP
SEC CIK: 1811063

Advertisement
300 × 250

See a number that looks wrong?